Zimmer and Peacock is an ISO13485 contract developer and manufacturer of electrochemical biosensors and in-vitro diagnostics (IVD), where our business model is to receive commissions to develop and manufacture electrochemical diagnostic products in line with the customer requirements.
One of the biggest markets for IVD contract development and manufacture is cardiovascular diagnostic testing.
At the time of writing the Cardiovascular Diagnostic Testing Market is approximately 6.8 billion USD, though with a compound annual growth rate (CAGR) of 8.3 %, this is expected to reach 15.4 billion USD by 2030. The growth in the market is due to both an ageing population and an increasing awareness of testing for diagnosing disease and disorders, including: arrhythmias, myocardial injury and acute coronary syndrome. Approximately 90 % of the diagnostic market today is IVD, which is a technology that particularly lends itself to ZP's electrochemical IVD platform. As with many health related technologies the biggest markets are in North America, but the fastest growing markets are in Asia-Pacific.
The biomarkers for cardiovascular disease are often proteins, that can be detected using ZP's electrochemical immunoassay technology, an non-exhaustive list of biomarkers for cardiovascular disease, includes: Troponins, IL-6, Fibrinogen, NT-proBNP, Lipoproteins A, Osteoprotegerin, VCAM-1, Pentraxin 3, MMP-9, MCP-1, Adiponectin.